Latest news with #Risinger
Yahoo
4 days ago
- Business
- Yahoo
Why Roivant Sciences Stock Bounced Back on Tuesday
Key Points A day after it published its latest set of quarterly earnings, an analyst bumped his price target higher. He also maintained his equivalent of a buy recommendation. 10 stocks we like better than Roivant Sciences › Monday's hangover turned into Tuesday's party for healthcare stock Roivant Sciences (NASDAQ: ROIV). On the back of a modest but meaningful analyst price target hike, investors bid the stock up by nearly 4% following a post-earnings slide the day before. With the Tuesday rise, Roivant handily beat the benchmark S&P 500 index, which bumped 1.1% higher. Boosting the biotech Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his recommendation of outperform (read: buy) on the company's stock. According to reports, Risinger's adjustment is based on a change in his forecast for the biotech company's share count. The analyst based this on management's statements about its share repurchase program, which is expected to shave the tally for shares outstanding. As for Roivant's operations, the pundit waxed bullish on the eventual outcome of the company's phase 3 clinical trial of brepocitinib in the treatment of dermatomyositis, a rare inflammatory disease that can affect the muscles and the skin. He's anticipating a readout of the trial to be published in the second half of this year. A first quarter to forget Risinger's continued bullishness on Roivant was a morale-booster for the market, which had traded out of the company's shares after Monday's fiscal first quarter of 2026 earnings release. The company reported significantly lower revenue compared to the same period of 2025, and it flipped to a net loss on the bottom line. Should you buy stock in Roivant Sciences right now? Before you buy stock in Roivant Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roivant Sciences wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy. Why Roivant Sciences Stock Bounced Back on Tuesday was originally published by The Motley Fool Sign in to access your portfolio
CNBC
08-07-2025
- Business
- CNBC
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
We're back from the holiday weekend with President Donald Trump's "big beautiful" bill officially signed into law. His landmark tax cut and spending package includes more than $1 trillion cuts to Medicaid, which will leave millions of vulnerable Americans without health insurance and threaten the hospitals and centers that provide care to them. While the health-care spending reductions will have massive human costs, they will also affect the pharmaceutical industry. Medicaid only accounts for a portion of many drugmakers' revenue in the U.S. – and an even smaller share of their total revenue worldwide. Medicaid also reimburses companies for drugs at lower rates than those in other programs like Medicare or commercial insurance, according to a Monday note from Leerink Partners analyst David Risinger. That's largely due to a program that requires drug manufacturers to provide rebates to states in exchange for Medicaid coverage of their drugs, resulting in lower net drug prices. Still, Risinger said "future loss of revenue is a marginal negative" for drugmakers. He also said some companies' sales are more exposed to the Medicaid market than others, based on previous company commentary and his firm's internal estimates. Vertex Pharmaceuticals and Gilead rely more on Medicaid than other large-cap pharmaceutical companies, Risinger said. Medicaid accounts for 25% of Vertex's U.S. revenue and 22% of Gilead's domestic sales, according to the note. Vertex disclosed at a conference in June that Medicaid accounts for 23% of sales from its cystic fibrosis medicines, which are the company's key revenue drivers. That tracks: Half of all children and a third of all adults with that genetic condition rely on Medicaid to afford the treatments and care they need to live a healthy life, according to the Cystic Fibrosis Foundation. Medicaid also plays a large role in HIV prevention and treatment, especially for underserved populations, which is a core focus for Gilead. For example, the company's HIV treatment pill Biktarvy was ranked the second-highest in terms of total Medicaid drug spending in 2022, and was still one the most widely used drugs in the program in 2024, according to a note from Jefferies analysts in March. Still, the analysts said the hit Gilead's business will likely take from Medicaid cuts would be "manageable." The note was based on estimates from a previous version of the bill. Commercial insurers also provide the majority of coverage for HIV prevention and ongoing treatment, while Medicaid plays a smaller, though still important, role. Medicaid represents 15% of Roche's U.S. revenue, 12% of Johnson & Johnson's domestic sales (excluding its medical device business) and 12% of Novo Nordisk's U.S. revenue. Among major pharmaceutical companies, Bristol Myers Squibb and Pfizer had the lowest exposure, with just 4% of their U.S. revenues coming from Medicaid, each. Risinger noted that significant Medicaid cuts will not occur until after the November 2026 midterm elections, so any financial impacts to drugmakers will essentially begin in 2027. There's also one more important win for drugmakers in Trump's bill to take into account: a provision that will exempt more medicines from the Inflation Reduction Act's Medicare drug price negotiations. We'll continue to monitor the impact of legislation on the industry, so stay tuned. Feel free to send any tips, suggestions, story ideas and data to Annika at We're halfway through 2025, which means we have some fresh digital health funding data to review. Even in a volatile macroeconomic and policy environment, the sector saw "strong momentum," according to a new report from Rock Health. Digital health companies in the U.S. received $6.4 billion in funding in the first half of the year, up from $6 billion in the same period last year and $6.2 billion in the first half of 2023, the report said. The sector raised $3.4 billion in venture funding in the second quarter alone, up substantially from the average of $2.6 billion per quarter since 2023. Startups that use artificial intelligence as a core part of their product raised 62% of all digital health venture funding during the first half of the year, the first time that AI-enabled companies have captured a majority of the fresh capital. These businesses pulled in an average of $34.4 million per round. "Digital health is proving it is more than just steady and resilient; the sector is entering a new phase of traction and impact, with AI playing a linchpin role," Rock Health said. But while funding is up, deal count is down slightly. Digital health companies closed 245 deals in the first half of the year, while they closed 273 in the same period last year, the report said. Even so, megadeals, or raises above $100 million, are rising. There were 11 megadeals in the first half of the year, which is on pace to pass the 17 megadeals that took place in all of 2024. There has also been a flurry of M&A activity within digital health this year. The sector closed 107 M&A agreements in the first half of 2025, which could quickly top the 121 total M&A deals that closed in 2024. And, much to the relief of many digital health investors, Hinge Health and Omada Health took the leap and debuted on the public markets. Rock Health said these exits were undeniably "the breakout moments of 2025 so far." "These public market debuts have given investors much-needed redemption after an exit drought, tough public market performances, and a string of recent take-privates," Rock Health said. Read the full report here. Feel free to send any tips, suggestions, story ideas and data to Ashley at
Business Insider
05-07-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Amedisys (AMED) and Xoma (XOMA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Corbus Pharmaceuticals (CRBP – Research Report), Amedisys (AMED – Research Report) and Xoma (XOMA – Research Report). Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Corbus Pharmaceuticals (CRBP) LifeSci Capital analyst Dennis Kennedy maintained a Buy rating on Corbus Pharmaceuticals on July 1 and set a price target of $53.00. The company's shares closed last Thursday at $7.71, close to its 52-week low of $5.49. According to Kennedy is ranked #3144 out of 9710 analysts. Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $43.14. Amedisys (AMED) In a report issued on June 30, Whit Mayo from Leerink Partners maintained a Hold rating on Amedisys, with a price target of $101.00. The company's shares closed last Thursday at $96.10. According to Mayo is a 3-star analyst with an average return of 2.7% and a 49.4% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Clover Health Investments, and Pediatrix Medical Group. Currently, the analyst consensus on Amedisys is a Hold with an average price target of $100.67. Xoma (XOMA) Leerink Partners analyst David Risinger maintained a Buy rating on Xoma on June 30. The company's shares closed last Thursday at $26.96. According to Risinger is a 5-star analyst with an average return of 8.5% and a 53.0% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Centessa Pharmaceuticals, and Vertex Pharmaceuticals. Currently, the analyst consensus on Xoma is a Strong Buy with an average price target of $69.50.
Business Insider
19-06-2025
- Business
- Business Insider
Leerink Partners Keeps Their Buy Rating on Tenax Therapeutics (TENX)
Leerink Partners analyst David Risinger reiterated a Buy rating on Tenax Therapeutics (TENX – Research Report) yesterday. The company's shares closed yesterday at $5.67. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Risinger is a 5-star analyst with an average return of 8.7% and a 52.65% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Regeneron. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenax Therapeutics with a $21.67 average price target.
Yahoo
02-05-2025
- Business
- Yahoo
Eli Lilly stock sell-off was 'overreaction': Analysts
Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. The move, some analysts say, was an overreaction to the news that GLP-1 competitor Novo Nordisk (NVO) locked up a preferred listing deal with CVS (CVS) on its formulary for obesity drug Wegovy to the exclusion of Eli Lilly's drug Zepbound. "We think the market reaction was overdone and are thus reiterating our OP [Outperform] rating on LLY," Leerink Partners analyst David Risinger wrote in a note to clients Friday. Risinger also lowered Eli Lilly's price target from $989 to $944 on the formulary news, calling it a negative in a note Thursday. Read more about Eli LIlly's stock moves and today's market action. The deal with CVS is the latest this week as Novo Nordisk pushes for more access points for Wegovy, which has been overtaken in weekly prescription fillings by Eli Lilly's Zepbound, including deals with telehealth platforms like Hims & Hers (HIMS). It's a key reason why Novo Nordisk's stock is down more than 25% in the past two months. "LLY is taking ~75% share on new branded obesity scripts," Jefferies analyst Akash Tewari wrote in a note to clients Thursday. He questioned whether Novo Nordisk's move was the right one. This also sparked concern that Novo Nordisk's moves could hamper Eli Lilly's momentum — and launch a price war — which pressured Eli Lilly's stock Thursday. Eli Lilly's stock looked to be slightly reversing its losses in trading Friday, up more than 4% at market open. "The move today reminds of what we say frequently: expect volatility, take advantage of moment of weakness, as long as there is not a new, fundamental crack in the story — no such cracks surfaced today, in our opinion," BofA Securities analyst Tim Anderson wrote in a note to clients Thursday. The overarching concern with the CVS/Novo Nordisk deal is whether this starts a race to the bottom on pricing between the two GLP-1 market leaders. The stock action Thursday assumed the CVS move would drive down price, and therefore profits, for both companies in the GLP-1 market, driven by a "desperate" Novo Nordisk, BofA's Anderson said. Eli Lilly CEO David Ricks signaled he was not interested in such a race and instead is focusing on near-term wins with next-generation GLP-1s and the highly anticipated orforglipron, an obesity pill that could hit the markets mid-next year. "We're not interested in exclusive deals. We think innovation and choice is very important. And we're well into the product replacement cycle, and there's more coming," Ricks told Yahoo Finance. That sentiment was reflected in some analyst notes late Thursday. Jefferies' Tewari wrote in a note that Lilly still "has one of the most sustainable growth stories in the next 5-10 years." He expressed doubt that the impacted pool of patients would be significant and shrugged off the idea that this was the starting gun of a price war. "We're skeptical that NVO is making irrational pricing decisions & that a single formulary will lead to a race to the bottom on pricing," he wrote. JPMorgan's Chris Schott similarly wrote, "We do not see the CVS announcement as portending an acceleration in price declines across the space," and he does not see this as "leading to a price war." BofA's Anderson had a slightly different take. "It's not to say that there's not going to be erosion in price, I mean there is, each and every year. This is not a sudden step-change. I think it's being taken out of proportion," he said. But time will tell if the move is a desperate one on the part of either CVS or Novo Nordisk, with broader impacts, or one that doesn't move the needle at all. "I do think Novo, they are trying to prove to their shareholders that they're going to see inflection of their franchise and return to growth later in the year. That's why they signed that Hims deal, that's why they can talk about the CVS deal. I think this is free advertising for CVS and Novo," BofA's Anderson said. "I think Novo is trying to convey ... there's always negotiations with payers, but they're not out there undermining a market. And that's how Lilly's stock is reacting," he said, adding CVS may have been overstating the impact of the formulary decision on the call. Most analysts said the impact on Eli Lilly should be limited and that a key indicator would be employer-sponsored insurance plans and how they react to the formulary option. "It remains to be seen how attractive this change will be to employers given differences in product profiles while patients could also look to go through exemption processes to keep their prescriptions," Schott wrote. He added, "LLY noted that the change primarily impacts smaller employers, who likely have lower employer opt-in rates on average (while larger employers largely utilize more customized formularies)." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Sign in to access your portfolio
